Cytotoxicity of 5-fluoro-2'-deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate
- PMID: 147465
- PMCID: PMC411383
- DOI: 10.1073/pnas.75.2.980
Cytotoxicity of 5-fluoro-2'-deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate
Abstract
Protein in vitro inhibition of thymidylate synthase (5,10-methylenetetrahydrofolate:dUMP C-methyltransferase, EC 2.1.1.45) by 5-fluoro-2'-deoxyuridylate requires 5,10-methylenetetrahydrofolate. The cytoxicity of 5-fluoro-2'-deoxyuridine towards cultured L1210 mouse leukemia cells is reduced when intracellular reduced folates are depleted, either by limiting the source in media or by inhibition of dihydrofolate reductase with methotrexate. Likewise, the intracellular amount of 5-fluoro-2'-deoxyuridylate covalently bound to thymidylate synthase in L1210 cells treated with 5-fluoro-2'-deoxyuridine is greatly diminished when cells are depleted of folate cofactors. The folate requirement for optimal growth of L1210 cells is lower than that required for maximal cytotoxicity of 5-fluoro-2'-deoxyuridine. These findings provide a biochemical rationale that may be useful in designing clinical protocols that use 5-fluorinated uracil analogs.
Similar articles
-
Folate-pool interconversions and inhibition of biosynthetic processes after exposure of L1210 leukemia cells to antifolates. Experimental and network thermodynamic analyses of the role of dihydrofolate polyglutamylates in antifolate action in cells.J Biol Chem. 1989 Oct 15;264(29):17016-23. J Biol Chem. 1989. PMID: 2529254
-
Role for cytosolic folate-binding proteins in the compartmentation of endogenous tetrahydrofolates and the 5-formyl tetrahydrofolate-mediated enhancement of 5-fluoro-2'-deoxyuridine antitumor activity in vitro.Cancer Res. 1990 Jun 1;50(11):3262-9. Cancer Res. 1990. PMID: 2139802
-
Role of methylenetetrahydrofolate depletion in methotrexate-mediated intracellular thymidylate synthesis inhibition in cultured L1210 cells.Cancer Res. 1988 Jun 15;48(12):3398-404. Cancer Res. 1988. PMID: 3370638
-
Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.Cancer Res. 1986 Jun;46(6):2810-5. Cancer Res. 1986. PMID: 2938731
-
Anti-folate toxicity and its reversal.Biochem Soc Trans. 1976;4(5):856-9. doi: 10.1042/bst0040856. Biochem Soc Trans. 1976. PMID: 793905 Review. No abstract available.
Cited by
-
Lack of enhanced cytotoxicity of cultured L1210 cells using folinic acid in combination with sequential methotrexate and fluorouracil.Cancer Chemother Pharmacol. 1985;15(3):214-9. doi: 10.1007/BF00263888. Cancer Chemother Pharmacol. 1985. PMID: 3876889
-
Clinical pharmacology of 5-fluorouracil.Clin Pharmacokinet. 1989 Apr;16(4):215-37. doi: 10.2165/00003088-198916040-00002. Clin Pharmacokinet. 1989. PMID: 2656050 Review.
-
Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer.Invest New Drugs. 2015 Oct;33(5):1078-85. doi: 10.1007/s10637-015-0272-0. Epub 2015 Jul 21. Invest New Drugs. 2015. PMID: 26189513 Free PMC article. Clinical Trial.
-
The pharmacokinetics of reduced folates after intraperitoneal and intravenous administration of racemic [6S,R]-folinic acid.Cancer Chemother Pharmacol. 1994;35(2):144-8. doi: 10.1007/BF00686637. Cancer Chemother Pharmacol. 1994. PMID: 7987991
-
5-Fluorouracil metabolism and cytotoxicity after pre-treatment with methotrexate or thymidine in human hypopharynx and colon carcinoma xenografts: a 19F-nuclear magnetic resonance spectroscopy study in vivo.Cancer Chemother Pharmacol. 1996;37(3):259-65. doi: 10.1007/BF00688326. Cancer Chemother Pharmacol. 1996. PMID: 8529287
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources